

FUSED IMIDAZOLE COMPOUNDS AND REMEDIES FOR DIABETES MELLITUS

Publication number: WO0102400

Publication date: 2001-01-11

Inventor: ASANO OSAMU (JP); HARADA HITOSHI (JP); YOSHIKAWA SEIJI (JP); WATANABE NOBUHISA (JP); INOUE TAKASHI (JP); HORIZOE TATSUO (JP); YASUDA NOBUYUKI (JP); OOHASHI KAYA (JP); MINAMI HIROE (JP); NAGAOKA JUNSAKU (JP); MURAKAMI MANABU (JP); KOBAYASHI SEIICHI (US); TANAKA ISAO (JP); KAWATA TSUTOMU (JP); SHIMOMURA NAOYUKI (JP); AKAMATSU HIROFUMI (JP); OZEKI NAOKI (JP); SHIMIZU TOSHIKAZU (JP); HAYASHI KENJI (JP); HAGA TOYOKAZU (JP); NEGI SHIGETO (JP); NAITO TOSHIHIKO (JP)

Applicant: EISAI CO LTD (JP); ASANO OSAMU (JP); HARADA HITOSHI (JP); YOSHIKAWA SEIJI (JP); WATANABE NOBUHISA (JP); INOUE TAKASHI (JP); HORIZOE TATSUO (JP); YASUDA NOBUYUKI (JP); OOHASHI KAYA (JP); MINAMI HIROE (JP); NAGAOKA JUNSAKU (JP); MURAKAMI MANABU (JP); KOBAYASHI SEIICHI (US); TANAKA ISAO (JP); KAWATA TSUTOMU (JP); SHIMOMURA NAOYUKI (JP); AKAMATSU HIROFUMI (JP); OZEKI NAOKI (JP); SHIMIZU TOSHIKAZU (JP); HAYASHI KENJI (JP); HAGA TOYOKAZU (JP); NEGI SHIGETO (JP); NAITO TOSHIHIKO (JP)

Classification:

- International:

A61P3/10; A61P43/00; C07D471/04; C07D473/00; C07D473/34; C07D473/40; A61P3/00; A61P43/00; C07D471/00; C07D473/00; (IPC1-7): C07D473/34; A61K31/437; A61K31/52; A61K31/522; A61P3/10; A61P43/00; C07D213/73; C07D213/75; C07D235/18; C07D239/48; C07D471/04; C07D471/08; C07D473/18; C07D473/40; C07D487/04

- European:

C07D471/04; C07D473/00; C07D473/34; C07D473/40

Application number: WO2000JP04358 20000630

Priority number(s): JP19990188484 19990702; JP20000143495 20000516; JP20000182786 20000619

Also published as:

EP1221444 (A1)
WO0102400 (A1)
US6841549 (B1)
CA2376835 (A1)
EP1221444 (B1)

[more >>](#)

Cited documents:

JP11263789
WO9957103
JP10182636
WO9839344
US4728644
[more >>](#)

Abstract of WO0102400

Novel fused imidazole compounds of general formula (I), pharmacologically acceptable salts thereof, or hydrates of both, exhibiting adenosine A₂ receptor antagonism and being effective in the prevention and treatment of diabetes mellitus and complications of diabetes; wherein R<1> is optionally alkylated amino or the like; R<2> is hydrogen, alkyl, or the like; R<3> is optionally substituted aryl, a pyridinone group, a pyrimidinone group, or the like; Ar is an optionally substituted aryl or heteroaryl group, or the like; and Q and W are each independently N or CH.

Data supplied from the esp@cenet database - Worldwide

[Report a data error here](#)